secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001837607-25-000027
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma appoints Jost Fischer Interim CEO and Jennifer Sy as principal financial officer
--------------------------------------------------------------------------------

- On April 3, 2025, Board formally appointed Jost Fischer as Interim President, CEO and principal executive officer, effective April 4, 2025.
- Board appointed Jennifer Sy as Chief Accounting Officer and principal financial officer, effective April 4, 2025.
- Ms. Sy previously served as VP, Corporate Controller since August 2023; base salary increased to $275,000 from $245,000.
- Mr. Fischer continues as Chairman of the Board; no other compensation changes disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/0001837607-25-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000027/aeon-20250403x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer